Benzyl­ethyl­dimethyl­ammonium bromide

The crystal structure of the title compound, C11H18N+·Br−, has been determined as part of an ongoing study of the influence of the alkyl chain length on amphiphilic activity of quaternary ammonium salts. The title salt forms a three-dimensional network of ionic contacts through weak C—H⋯Br hydrogen bonds, with donor–acceptor distances in the range 3.757 (2)–3.959 (2) Å, in which methyl groups serve as donors

7-Methoxy-2-phenylchroman-4-one

In the title compound, C 16 H 14 O 3 , the ring O atom and the two adjacent non-fused C atoms, as well as the attached phenyl ring, exhibit static disorder [occupancy ratio 0.559 (12): 0.441 (12)]. The crystal packing features – [centroid– centroid distance = 3.912 (1) A ̊ ] and C—H interactions.In the title compound, C16H14O3, the ring O atom and the two adjacent non-fused C atoms, as well as the attached phenyl ring, exhibit static disorder [occupancy ratio 0.559 (12):0.441 (12)]. The crystal packing features [pi]-[pi] [centroid-centroid distance = 3.912 (1) Å] and C-H...[pi] inter­actions

Triple-negative breast cancer with ACTH-dependent Cushing's syndrome : case report

Introduction: Endocrine and metabolic paraneoplastic syndromes in the course of malignant tumors result from ectopic production of hormones or hormone precursors in tumor cells. Production of hormones by endocrine tumors is relatively frequent, while such production by adenocarcinoma cells is definitely rare. The study presents a case of triple-negative invasive breast cancer, with the ectopic secretion of ACTH (adrenocorticotropic hormone), which provokes serious metabolic disorders. Materials and methods: The patient was admitted to hospital with symptoms of Cushing`s syndrome. Diagnostic tests revealed that the cause of metabolic disorders was breast cancer. After proper preparation, the patient was qualified for surgery. Results: After the mastectomy, the patient’s metabolism stabilized. The patient underwent adjuvant chemotherapy and radiotherapy. Four months after the last cycle of systemic treatment, cancer dissemination was found. The patient was treated with second-line chemotherapy, however, control CT revealed progression. The patient died 20 months after surgery and two months after the last cycle of chemotherapy. Conclusions: The case reported in this study – triple-negative invasive breast cancer, responsible for ectopic production of ACTH and causing Cushing’s syndrome – is a rare phenomenon. Treatment of patients with breast cancer showing hormonal activity should not differ from general rules applied for breast cancer. However, due to accompanying metabolic disturbances, the patients need individualized oncological approach, precise diagnostic tests, and adequate preoperative preparation

(2Z)-2-Anilino-2-[oxido(phen­yl)iminio]-N-(2-pyrid­yl)acetamide methanol 0.425-solvate

The title compound, C19H16N4O2·0.425CH4O, crystallizes with two formula units per asymmetric unit. Researching its crystal structure constitutes part of a study of the nature of inter­actions between the N+—O− group and the vicinal NH group. The nitrone group and methanol solvent mol­ecules are linked via four N—H⋯O and one O—H⋯O hydrogen bonds, with donor–acceptor distances of 2.603 (3)–2.730 (3) and 2.770 (3) Å, respectively. The crystal structure also involves two intermolecular N—H⋯N hydrogen bonds

Mondor's disease in a patient after a mammotome biopsy

Mondor's disease is a rare, benign condition characterised by thrombophlebitis affecting subcutaneous veins of the chest and/or abdomen without an accompanying inflammatory response. The disease has a multifactorial etiology and its course is benign. It is usually self-limiting or it is eliminated by local treatment. Mondor's disease in the thoracoepigastric region may be a rare complication of mammotome biopsy. The case presentation describes a 32-year-old patient with Mondor's disease in the thoracoepigastric region after an ultrasound-guided mammotome biopsy of a breast. In the histopathological examination the lesion was diagnosed as fibroadenoma. Regardless of the disease's etiology, it is recommended to carry out diagnostic examinations to exclude co-occurring breast cancer

Synthesis, structure and properties of V(V) monooxido complex with ONO tridentate Schiff base

The oxidovanadium(V) Schiff base complex of formula [VO(L)(EtO)(EtOH)] (where H2L = Schiff base ligand derived from 5-methoxysalicylaldehyde and phenylacetic hydrazide) was synthesized and described. Complex crystalizes in triclinic P-1 space group. Octahedral geometry of the vanadium(V) centre is filed with oxido, ONO L2- ligand and two solvent molecules both in ethoxo and as neutral ethanol form. The complex is neutral, with 5- and 6-memebered ring formed by ONO ligand coordinated in octahedral plane with oxido and EtOH ligands in vertical positions. Two isomers are present in the unit cell, with different position of 5-membered ring versus vertical plane. The elemental analysis, magnetic susceptibility, thermogravimetry and spectroscopy (IR, UV-Vis) measurements were measured and are discussed. The cyclic voltammetry measurements show irreversible processes for vanadium(IV/V) redox system. Thermal stability both in a solid state (TG and SDTA measurements) as well as in solutions (at pH 7.0 and 2.0, studied by UV-Vis spectroscopy) is discussed

Thermal and long period stability of series of V(V), V(IV) and V(III) complex with Schiff base ligands in solid state

The synthesis and physicochemical properties of three new complexes of vanadium at +5, +4 and +3 oxidation state are described and discussed. The octahedral surrounding of vanadium for V(III) complexes of [V(L1)(HL1)] general formula is filled with two ONO tridentate ligand L, for V(IV) one ONO ligand L, oxido ligand and 1,10-phenanthroline (phen) as a co-ligand are presented in complexes of [VO(L2)(phen)]. For V(V) the complexes of [VO2(L1)(solv)] type were formed. As ligands, the H2L Schiff bases were formed in reaction between 5-hydroxysalcylaldehyde and phenylacetic hydrazide (H2L1) and 3,5- dichlorosalicyaldehyde and 4-hydroxybenzhydrazide (L2). The magnetic moment measurements, in 8 year period, show, that V(III) complexes slowly oxidise to V(IV) with preservation of the nonoxido character of the complexes, while V(IV) complexes were found to be stable. The TG and SDTA measurements indicate, that thermal stability depends mainly on the oxidation state of vanadium. The less thermally stable are the V(V) complexes, while V(IV) and V(III) are stable up to ca. 200oC. In solution, at pH 2 (similar to that in human digestion system), again the V(IV) are the most stable, only at pH 7.0 V(III) complexes had higher stability. The most stable, thus best for pharmaceutical use, are V(IV) complexes